Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research Annual Meeting 2026
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm Programs
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Sankamap Expands Exploration Footprint at Fauro as Systematic Prospecting Advances and New Gold Targets Emerge
NevGold Defines Multiple High-Priority Drill Targets Including Key Feeder Structures at Nutmeg Mountain Gold Project, Idaho
Brixton Drills 58 m of 0.50 g/t AuEq and 17.6 m of 1.47 g/t AuEq in the Glenfiddich Zone at Camp Creek, Thorn Project
SAGA Metals Advances Radar Project to Stage 2 RCL Optimization Targeting First High-Purity Titanium, Vanadium and Iron Products
